The 5-Alpha Reductase Inhibitor Finasteride Reduces Dyskinesia in a Rat Model of Parkinson’s Disease

    January 2017 in “ Experimental Neurology ”
    Roberto Frau, Paola Savoia, Silvia Fanni … Manolo Carta
    Studysummary This study found that finasteride significantly reduced levodopa-induced dyskinesia in both male and female rats without diminishing l-DOPA's motor benefits, indicating potential for clinical trials in Parkinson's patients.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on sciencedirect.com →
    Discuss this study in the Community →

    Research cited in this study 12

    1. Neuroactive Gonadal Drugs for Neuroprotection in Male and Female Models of Parkinson's Disease Neuroscience & Biobehavioral Reviews · 2015
    2. The Neurosteroidogenic Enzyme 5α-Reductase Modulates the Role of D1 Dopamine Receptors in Rat Sensorimotor Gating Psychoneuroendocrinology · 2015
    3. The 5α-Reductase Inhibitor Dutasteride but Not Finasteride Protects Dopamine Neurons in the MPTP Mouse Model of Parkinson’s Disease Neuropharmacology · 2015
    4. Targeting Neurosteroid Synthesis as a Therapy for Schizophrenia-Related Alterations Induced by Early Psychosocial Stress Schizophrenia Research · 2015
    5. Inhibition Of 5α-Reductase Attenuates Behavioral Effects Of D1-, But Not D2-Like Receptor Agonists In C57BL/6 Mice Psychoneuroendocrinology · 2012
    6. Finasteride Attenuates Pathological Gambling in Patients With Parkinson's Disease Journal of Clinical Psychopharmacology · 2012
    7. Inhibition of 5α-Reductase in the Nucleus Accumbens Counters Sensorimotor Gating Deficits Induced by Dopaminergic Activation Psychoneuroendocrinology · 2011
    8. A Preliminary Study of Finasteride in Tourette Syndrome Movement Disorders · 2011
    9. Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders Current Pharmaceutical Design · 2011
    10. Treatment of Benign Essential Blepharospasm With Finasteride Clinical Neuropharmacology · 2010
    11. Antipsychotic-Like Properties of 5-Alpha-Reductase Inhibitors Neuropsychopharmacology · 2008
    12. Treatment of Tourette’s Syndrome With Finasteride American Journal of Psychiatry · 2007